| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/17/2004 | WO2004050117A1 Proteins involved in the regulation of energy homeostasis |
| 06/17/2004 | WO2004050116A1 Protease inhibitor |
| 06/17/2004 | WO2004050115A2 Combination treatment using exendin-4 and thiazolidinediones |
| 06/17/2004 | WO2004050114A1 Novel agent for improving neurotransmission failure |
| 06/17/2004 | WO2004050088A1 Jnk inhibitor |
| 06/17/2004 | WO2004050082A1 The novel coumarin-amide derivatives and its preparation, said drug composition and its use |
| 06/17/2004 | WO2004050077A1 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy |
| 06/17/2004 | WO2004050075A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 06/17/2004 | WO2004050074A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 06/17/2004 | WO2004050039A2 Spirocyclic ureas, compositions containing such compounds and methods of use |
| 06/17/2004 | WO2004012651A3 Composition for heart disease, method to prepare same and uses thereof |
| 06/17/2004 | WO2004003164A3 Methods of organ regeneration |
| 06/17/2004 | WO2003106660A3 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/17/2004 | WO2003102138A3 Elongase genes and uses thereof |
| 06/17/2004 | WO2003053997A3 Methods of increasing endogenous erythropoietin (epo) |
| 06/17/2004 | WO2003051911A3 Gmg-5 polynucleotides and polypeptides and uses thereof |
| 06/17/2004 | WO2003040392A3 Nucleic acids encoding very long chain fatty acid biosynthesis enzymes |
| 06/17/2004 | WO2003032810A3 Treatment and diagnosis of insulin resistant states |
| 06/17/2004 | US20040116738 Conjugated unsaturated glyceride mixtures and a method for producing the same |
| 06/17/2004 | US20040116715 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 06/17/2004 | US20040116708 Carboxylic acids |
| 06/17/2004 | US20040116703 Central nervous system disorders, nicotinic acetylcholine receptors; endocrine diseases; antiinflammatory agents; analgesics; drug dependency; skin disorders; Alzheimer's and Parkinson's disease |
| 06/17/2004 | US20040116699 Melanocortin receptor agonists |
| 06/17/2004 | US20040116697 Novel compounds |
| 06/17/2004 | US20040116498 Regulations of lipids and/or bone density and compositions therefor |
| 06/17/2004 | US20040116495 Compounds and methods |
| 06/17/2004 | US20040116487 Novel oxazole derivatives |
| 06/17/2004 | US20040116486 Metalloproteinase inhibitors |
| 06/17/2004 | US20040116483 Glucagon antagonists/inverse agonists |
| 06/17/2004 | US20040116472 inhibit angiogenesis, tumor metastasis and growth, osteoporosis, Paget's disease, hypercalcemia of malignancy, retinopathy, macular degeneration, arthritis, periodontal disease, smooth muscle cell migration and viral diseases |
| 06/17/2004 | US20040116463 excellent in stability than amorphous one and are more preferable for treatment of hyperlipidemia and atherosclerosis |
| 06/17/2004 | US20040116455 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 06/17/2004 | US20040116454 Pyrazole compounds useful as protein kinase inhibitors |
| 06/17/2004 | US20040116440 Useful for diagnosis, treatment of male or female sexual dysfunction |
| 06/17/2004 | US20040116426 Small molecules useful in the treatment of inflammatory disease |
| 06/17/2004 | US20040116424 Aryl imidazoles and related compounds as C5a receptor modulators |
| 06/17/2004 | US20040116423 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| 06/17/2004 | US20040116417 Thiohydantoins and use thereof for treating diabetes |
| 06/17/2004 | US20040116416 having immunomodulating and cytokine-release-inhibiting action |
| 06/17/2004 | US20040116415 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 06/17/2004 | US20040116386 Resveratrol-phospholipids complexes, their preparation, and pharmaceutical and cosmetic composition containing same |
| 06/17/2004 | US20040116357 For prophylaxis and therapy of hyperglycemia such as diabetes, diabetic complications or obesity |
| 06/17/2004 | US20040116355 Caspase inhibitors and the use thereof |
| 06/17/2004 | US20040116353 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 06/17/2004 | US20040116336 Peptide derivatives |
| 06/17/2004 | US20040116328 Condensed imidazole derivatives |
| 06/17/2004 | US20040115805 CD56 positive human adult pancreatic endocrine progenitor cells |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040115666 Method for identifying compounds modulating reverse cholesterol transport |
| 06/17/2004 | US20040115331 Suitable for inclusion in food |
| 06/17/2004 | US20040115309 Food supplement |
| 06/17/2004 | US20040115288 Method for producing vitamin b enriched preparations from grasses |
| 06/17/2004 | US20040115264 Bioavailability |
| 06/17/2004 | US20040115261 Controlled delivery of tetracycline compounds and tetracycline derivatives |
| 06/17/2004 | US20040115202 monospecific antibody which specifically binds an epitope of a mammalian DPPIV (dipeptidyl peptidase IV, also known as CD26). |
| 06/17/2004 | US20040115185 Placental alkaline phosphatase to control diabetes |
| 06/17/2004 | US20040115184 Methods and compositions for modifying apolipoprotein b mrna editing |
| 06/17/2004 | US20040115181 Composition for transmucosal adminstration containing conenzyme q as the active ingredient |
| 06/17/2004 | US20040115179 treating and preventing gastrointestinal diseases as well as lowering serum cholesterol |
| 06/17/2004 | CA2508914A1 Modulators of melanocortin receptor |
| 06/17/2004 | CA2508581A1 Spirocyclic ureas, compositions containing such compounds and methods of use |
| 06/17/2004 | CA2508319A1 Jnk inhibitors |
| 06/17/2004 | CA2507763A1 Fused 1,3-dihydro-imidazole ring compounds |
| 06/17/2004 | CA2507750A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 06/17/2004 | CA2507742A1 Novel azole derivatives |
| 06/17/2004 | CA2507665A1 Preventive or remedy for diseases caused by hyperglycemia |
| 06/17/2004 | CA2507186A1 Anilinopyrazole derivatives useful for the treatment of diabetes |
| 06/17/2004 | CA2485957A1 Protease inhibitor |
| 06/17/2004 | CA2481489A1 Cysteine protease inhibitor |
| 06/16/2004 | EP1428877A1 Novel protein and dna thereof |
| 06/16/2004 | EP1428822A2 1-phenylpiperazine derivative as modulators of dopamine neurotransmission |
| 06/16/2004 | EP1428820A1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications |
| 06/16/2004 | EP1428533A2 Use of thiazolidine- or pyrrolidine-derivatives of aminoacids as antihyperglycemic agents |
| 06/16/2004 | EP1428532A1 Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| 06/16/2004 | EP1428531A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
| 06/16/2004 | EP1428529A1 Apolipo protein e secretion promoters |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
| 06/16/2004 | EP1427758A2 Compositions and methods of treating diabetes |
| 06/16/2004 | EP1427755A2 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 06/16/2004 | EP1427729A1 Carbazole derivatives and their use as npy5 receptor antagonists |
| 06/16/2004 | EP1427722A2 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression |
| 06/16/2004 | EP1427720A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427718A1 Benzothiepine ileal bile acid transport inhibotors |
| 06/16/2004 | EP1427717A1 Bioprecursors for percutaneous application |
| 06/16/2004 | EP1427713A1 Benzothiazepine derivatives for the treatment of hyperlipidemia |
| 06/16/2004 | EP1427709A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427446A2 The use of effect pigments in ingested drugs |
| 06/16/2004 | EP1427445A2 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 06/16/2004 | EP1427437A1 Oxyntomodulin for preventing or treating excess weight |
| 06/16/2004 | EP1427434A2 Anti-inflammatory agent |
| 06/16/2004 | EP1427429A1 Compositions and methods for treating subjects with hyperglycemia |
| 06/16/2004 | EP1427427A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 06/16/2004 | EP1427425A1 Method of treatment of obesity and paralyzed muscle and ergogenic aids |
| 06/16/2004 | EP1427423A1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| 06/16/2004 | EP1427411A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo 3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 06/16/2004 | EP1427407A2 Fatty amine drug conjugates |
| 06/16/2004 | EP1427396A1 Dosage forms having prolonged active ingredient release |
| 06/16/2004 | EP1427297A1 Composition for reducing appetite in mammals comprising procyanidin |
| 06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |